{"id":12577,"date":"2026-07-16T15:53:17","date_gmt":"2026-07-16T05:53:17","guid":{"rendered":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/?p=12577"},"modified":"2026-07-16T15:59:40","modified_gmt":"2026-07-16T05:59:40","slug":"the-trip-were-not-ready-for-why-the-psychedelic-renaissance-is-getting-ahead-of-the-science","status":"publish","type":"post","link":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/the-trip-were-not-ready-for-why-the-psychedelic-renaissance-is-getting-ahead-of-the-science\/","title":{"rendered":"The Trip We\u2019re Not Ready For: Why the Psychedelic \u201cRenaissance\u201d Is Getting Ahead of the Science"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

There is a version of the psychedelics story that everyone already knows. A veteran who stopped waking up screaming. A cancer patient who made peace with dying. A depressive who, after decades of grey, felt sunlight again. These stories are moving, they are frequently true, and Netflix, bestselling books, presidential press conferences, and a booming investor class have spent the past several years turning them into a single, tidy narrative: psychedelics are the breakthrough that psychiatry has been waiting for.<\/p>

\"\"<\/p>

The trouble is that a good story is not the same thing as good evidence, and 2026 has been a rough year for anyone who assumed the two had already converged.<\/p>

The Blinding Problem No One Wants to Talk About<\/strong><\/p>

Start with the mechanics of a clinical trial. The entire point of a placebo-controlled study is that participants don\u2019t know which arm they\u2019re in \u2014 otherwise their expectations, not the drug, start doing the work. That\u2019s straightforward with a pill that produces no noticeable sensation. It is much harder when the \u201cdrug\u201d produces vivid hallucinations, ego dissolution, and hours-long emotional catharsis.<\/p>

A team of Canadian researchers decided to actually check how often this \u201cblinding\u201d was working in psychedelic trials. Reviewing 112 supposedly gold-standard studies of psilocybin, LSD, ketamine, MDMA, and DMT, they found that fewer than a third even bothered to test whether blinding had succeeded \u2014 and when they did check, it had failed more than 90 percent of the time for psilocybin, LSD, and DMT, and 85 percent of the time for MDMA. Only ketamine trials fared meaningfully better, because a sedative can plausibly mimic its effects. The researchers, writing in\u00a0JAMA Psychiatry<\/em>, concluded the existing trial results should be treated with real skepticism until this is fixed.<\/p>

That finding landed alongside two more studies that, together, amount to a significant gut-check for the field. A systematic review and meta-analysis by Zachary Williams and colleagues took the radical step of comparing psychedelic-assisted therapy not against a sham placebo pill, but against\u00a0open-label<\/em>\u00a0antidepressants \u2014 trials in which patients and doctors both know a real drug is being given, which is functionally what a \u201cblinded\u201d psychedelic trial actually is anyway. Pooling eight psychedelic trials against sixteen open-label antidepressant trials, they found the two produced nearly identical improvement on the standard depression scale \u2014 a difference of roughly three-tenths of a point in favor of the antidepressants, well within the margin of chance. In the same week, a separate triple-blind trial of psilocybin for treatment-resistant depression, led by Lea Mertens and funded independently of industry, added another disappointing data point to the pile.<\/p>

None of this means psychedelics do nothing. It means that when you strip away the placebo-inflating effect of a patient knowing, unmistakably, that they\u2019ve just taken a powerful hallucinogen, the advantage over existing treatments shrinks dramatically \u2014 in some analyses, to statistical noise. That is a far cry from \u201cthe results are in,\u201d a phrase Michael Pollan used in the Netflix adaptation of his bestseller\u00a0How to Change Your Mind<\/em>, and one that critics have pointed out simply isn\u2019t accurate.<\/p>

How a Book Became a Movement<\/strong><\/p>

It\u2019s worth pausing on Pollan specifically, because few individuals illustrate the gap between cultural momentum and scientific caution better than he does. His 2018 book turned psilocybin, MDMA, and LSD into dinner-party conversation for an audience that had previously associated them with Woodstock and burnout. The 2022 docuseries went further: reviewers at the time noted that by showcasing almost exclusively success stories, the show risked leaving casual viewers with the impression that psychedelic therapy is a near-universal cure, when even the most favorable clinical trials typically get only around a third of participants into full remission. One reviewer described the series as playing out like an infomercial for psychedelic-assisted therapy, right down to researchers on camera declaring that the debate was essentially settled.<\/p>

This is not a minor cultural footnote. It\u2019s the mechanism. Popular science journalism, celebrity podcasts, glossy docuseries, and \u2014 as of 2026 \u2014 the White House itself have been running well ahead of the peer-reviewed literature, and each layer of amplification tends to strip out the caveats that were present one step back. A tentative Phase 2 signal becomes a magazine feature; the magazine feature becomes a talking point on a wellness podcast; the talking point becomes political testimony. By the time the idea reaches a policymaker or a desperate patient, \u201cshows some promise in small, unblinded trials\u201d has quietly become \u201cthe results are in.\u201d<\/p>

We\u2019ve Run This Experiment Before<\/strong><\/p>

Psychiatry has a name for what happens when enthusiasm outruns evidence, because it has happened before \u2014 twice, on two continents, in living memory.<\/p>

The first round was psychedelic research itself. A wave of studies in the 1950s and \u201960s explored LSD for alcoholism and neurosis with real optimism, before the research collapsed amid moral panic, sloppy methodology, and the countercultural baggage that men like Timothy Leary attached to it. Researchers today openly acknowledge they\u2019re now roughly as far into the second wave of research as their predecessors got before that first one ground to a halt \u2014 which is less a triumphant milestone than an open question about whether history is about to rhyme.<\/p>

The second round was closer to home and much more recent: Australia\u2019s rollout of medicinal cannabis. Legalized in 2016 under intense public and political pressure, prescriptions exploded from a few hundred to more than a million within less than a decade, generating a market worth hundreds of millions of dollars. According to reporting compiled by the Dalgarno Institute, Australia\u2019s drug regulator fielded more than 600 adverse event reports between mid-2022 and mid-2025 \u2014 including dozens involving psychosis, over a dozen involving suicidal ideation, and cases of homicidal ideation \u2014 while acknowledging it hadn\u2019t actually investigated the safety of most of the products in question. By late 2025, the country\u2019s peak medical and pharmacy bodies were writing jointly to the health minister to warn about coercive prescribing practices and a system being exploited by commercial interests that had outpaced the regulatory infrastructure meant to contain them.<\/p>

Then, in February 2023, Australia became the first country in the world to down-schedule psilocybin and MDMA for clinical use \u2014 and it did so, according to the same reporting, over the explicit objection of its own expert advisory committee, which had cited the absence of completed Phase III trials, the difficulty of translating tightly controlled research settings into everyday clinical practice, and the fact that no approved psilocybin product existed anywhere on earth. An independent report commissioned to inform that very decision rated the certainty of the evidence as low to very low using the Cochrane GRADE framework. The regulator reversed its own interim caution after a lobbying campaign generated thousands of public submissions \u2014 submissions a delegate later noted were largely brief form responses that didn\u2019t engage with the substance of the committee\u2019s concerns at all.<\/p>

If that sequence sounds familiar, it\u2019s because the United States appears to be running a faster, higher-stakes version of it right now. In April 2026, an executive order directed the FDA and DEA to fast-track psilocybin, MDMA, and ibogaine, committed federal funding, and instructed regulators to establish expedited access pathways ahead of completed Phase III trials. Legal analysts at Harvard\u2019s Petrie-Flom Center noted the political theater surrounding the signing \u2014 and pointed out that one company\u2019s product had reportedly been pulled from a priority list and then abruptly reinstated in the same order, a detail that reads less like scientific sequencing than political stagecraft. Shares in psychedelic drug developers jumped on the news.<\/p>

The inclusion of ibogaine drew particular alarm from researchers, since the compound has documented cardiac risks \u2014 including a 2026 study finding it caused clinically significant heart-rhythm prolongation in half of subjects tested, in some cases for more than a day \u2014 and has not completed even Phase I trials in the United States.<\/p>

The Part the Highlight Reel Leaves Out<\/strong><\/p>

Beyond the numbers, there is a harder story that rarely makes it into a docuseries. The very quality that makes psychedelics interesting to therapists \u2014 the suggestibility and emotional openness they induce \u2014 is also what makes patients acutely vulnerable to the people supervising them. The most extensively documented case involves a PTSD trial participant whose sessions, later reviewed by journalists, showed her therapists behaving in ways so far outside professional norms that three related research papers were eventually retracted for ethical violations. That case wasn\u2019t a one-off; the FDA\u2019s 2024 rejection of an MDMA-assisted therapy application cited ongoing concerns about therapist misconduct alongside its concerns about trial design and functional unblinding, and a separate academic paper was later flagged for allegedly downplaying practices described by the therapists it interviewed.<\/p>

There is also, less dramatically, a straightforward conflicts-of-interest problem. One researcher in the field has remarked that he knows only a single colleague who has never personally used psychedelics \u2014 a level of insider enthusiasm that would raise eyebrows in almost any other area of drug development, and one that sits alongside a growing web of consulting fees flowing from psychedelic companies to the researchers publishing on their products.<\/p>

Caution Is Not the Same as Dismissal<\/strong><\/p>

None of this amounts to an argument that psychedelics have no therapeutic value, and it would be its own kind of overreach to claim otherwise. Some trials, imperfect as they are, do show genuine signal, particularly for narrowly defined, carefully screened populations under close supervision \u2014 a population and setting that bears little resemblance to how a drug behaves once it\u2019s prescribed at scale. But \u201cpromising in small, poorly blinded trials with a devoted research community\u201d is a meaningfully different claim than \u201ca proven, superior alternative to existing psychiatric medication,\u201d and the media apparatus surrounding psychedelics \u2014 bestselling books, glossy documentaries, celebrity podcasts, and now executive orders \u2014 has spent years collapsing that distinction.<\/p>

What the evidence currently supports is neither the panacea of the popular narrative nor blanket rejection, but something far less cinematic: the standard, unglamorous machinery of drug regulation \u2014 completed Phase III trials, active-comparator designs that account for unblinding, independent committee review insulated from public lobbying campaigns, mandatory long-term safety data, and real structural safeguards against therapist misconduct. That machinery exists precisely because moving individual stories are not, and have never been, a substitute for population-level evidence.<\/p>

Skipping it hasn\u2019t gone well before. There\u2019s little reason to expect this time to be different simply because the sales pitch has gotten better.<\/p>

Dalgarno Institute<\/p>

Sources: Orsini et al., \u201cBlinding Integrity in Psychedelic Randomized Clinical Trials,\u201d JAMA Psychiatry (2026); Williams, Barnett & Szigeti, \u201cPsychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions,\u201d JAMA Psychiatry (2026); Mertens et al., \u201cEfficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial,\u201d JAMA Psychiatry (2026); Dalgarno Institute, \u201cThe Psychedelic Movement in the US: A Risky Experiment?\u201d (2025) and \u201cWhen Politics Overrides Science: The Dangerous Rush to Psychedelic Medicine\u201d (2026); Psychedelic Spotlight and Overland literary journal reviews of Netflix\u2019s How to Change Your Mind (2022); additional reporting via Science Media Centre, Drug Discovery Trends, Petrie-Flom Center (Harvard Law), and Medical Xpress.<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

There is a version of the psychedelics story that everyone already knows. A veteran who stopped waking up screaming. A cancer patient who made peace with dying. A depressive who, after decades of grey, felt sunlight again. These stories are moving, they are frequently true, and Netflix, bestselling books, presidential press conferences, and a booming […]<\/p>\n","protected":false},"author":1,"featured_media":12578,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":"","_wp_rev_ctl_limit":""},"categories":[19],"tags":[],"class_list":["post-12577","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dalgarno-research-you-can-use"],"_links":{"self":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/12577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/comments?post=12577"}],"version-history":[{"count":2,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/12577\/revisions"}],"predecessor-version":[{"id":12582,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/posts\/12577\/revisions\/12582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/media\/12578"}],"wp:attachment":[{"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/media?parent=12577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/categories?post=12577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dalgarnoinstitute.org.au\/wp_site\/wp-json\/wp\/v2\/tags?post=12577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}